已收盤 08-07 16:00:00 美东时间
+0.050
+0.20%
Corporate credit ratings should continue improving across much of the U.S. market, providing support for already-tight credit spreads and reinforcing a constructive outlook for investment-grade and hi...
06-15 07:54
• 吉利德宣布其在研HIV治疗方案islatravir/lenacapavir的3期临床试验取得积极结果。 • FDA已授予bictegravir/lenacapavir HIV治疗方案申请优先审评资格。 • Livdelzi用于治疗原发性胆汁性胆管炎的3期IDEAL研究显示出积极结果。
06-11 16:16
– Novel Investigational Combination Pairs Merck's Islatravir, a Next-Generation Nucleoside Analog with Distinct Mechanisms of Action, Including Reverse Transcriptase Translocation Inhibition, with Gilead's Lenacapavir, a
06-09 04:36